In the CheckMate-066 study, nivolumab was also shown to associate with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated metastatic melanoma patients, without a BRAF mutation (94). This evidence concerns the gene BRAF and metastatic melanoma.